Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer

被引:5
作者
da Silva, Fernanda Cardoso [1 ]
Brandao, Douglas Cardoso [1 ]
Ferreira, Everton Allan [2 ]
Siqueira, Raoni Pais [1 ]
Ferreira, Helen Soares Valenca [1 ]
Da Silva Filho, Ademar Alves [2 ]
Araujo, Thaise Goncalves [1 ,3 ]
机构
[1] Univ Fed Uberlandia, Inst Biotechnol, Lab Genet & Biotechnol, BR-38700002 Patos De Minas, MG, Brazil
[2] Univ Fed Juiz de Fora, Fac Pharm, Dept Pharmaceut Sci, BR-36036900 Juiz De Fora, MG, Brazil
[3] Univ Fed Uberlandia, Inst Biotechnol, Lab Nanobiotechnol Prof Dr Luiz Ricardo Goulart Fi, BR-38405302 Uberlandia, MG, Brazil
关键词
breast cancer; hormone therapy; natural products; resistance; CELL-CYCLE ARREST; ESTROGEN-RECEPTOR-ALPHA; ENDOCRINE THERAPY RESISTANCE; NF-KAPPA-B; GROWTH-FACTOR; TUMOR-GROWTH; IN-VITRO; MAMMARY-GLAND; UP-REGULATION; MCF-7; CELLS;
D O I
10.3390/ph16101466
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Breast cancer (BC) is the most diagnosed cancer worldwide, mainly affecting the epithelial cells from the mammary glands. When it expresses the estrogen receptor (ER), the tumor is called luminal BC, which is eligible for endocrine therapy with hormone signaling blockade. Hormone therapy is essential for the survival of patients, but therapeutic resistance has been shown to be worrying, significantly compromising the prognosis. In this context, the need to explore new compounds emerges, especially compounds of plant origin, since they are biologically active and particularly promising. Natural products are being continuously screened for treating cancer due to their chemical diversity, reduced toxicity, lower side effects, and low price. This review summarizes natural compounds for the treatment of luminal BC, emphasizing the activities of these compounds in ER-positive cells. Moreover, their potential as an alternative to endocrine resistance is explored, opening new opportunities for the design of optimized therapies.
引用
收藏
页数:40
相关论文
共 50 条
[41]   Receptor tyrosine kinases as a therapeutic target by natural compounds in cancer treatment [J].
Balogun, Toheeb A. ;
Ige, Oluwasegun M. ;
Alausa, Abdullahi O. ;
Onyeani, Chijioke O. ;
Tiamiyu, Zainab A. ;
Omoboyowa, Damilola A. ;
Saibu, Oluwatosin A. ;
Abdullateef, Olayemi T. .
FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 7 (01)
[42]   Resveratrol in Cancer Treatment with a Focus on Breast Cancer [J].
Kowsari, Hamed ;
Davoodvandi, Amirhossein ;
Dashti, Fatemeh ;
Mirazimi, Seyed Mohamad Ali ;
Bahabadi, Zahra Razaghi ;
Aschner, Michael ;
Sahebkar, Amirhossein ;
Gilasi, Hamid Reza ;
Hamblin, Michael R. ;
Mirzaei, Hamed .
CURRENT MOLECULAR PHARMACOLOGY, 2023, 16 (03) :346-361
[43]   Anticancer potential of cryptotanshinone on breast cancer treatment; A narrative review [J].
Dalil, Davood ;
Iranzadeh, Saeid ;
Kohansal, Soroush .
FRONTIERS IN PHARMACOLOGY, 2022, 13
[44]   Promising Anticancer Potential of Herbal Compounds against Breast Cancer: A Systemic Review [J].
Vekaria, Mrudul ;
Tirgar, Pravin .
ASIAN JOURNAL OF PHARMACEUTICAL RESEARCH AND HEALTH CARE, 2021, 13 (02) :202-218
[45]   Natural bioactive compounds: a potential therapeutic strategy to sensitize bladder cancer to cisplatin treatment? Comment [J].
Ruiz de Porras, Vicenc .
CANCER DRUG RESISTANCE, 2022, 5 (02) :339-343
[46]   Molecular heterogeneity of luminal breast cancer [J].
Loi, S. .
BREAST CANCER RESEARCH, 2011, 13
[47]   The complex landscape of luminal breast cancer [J].
Lutz, Catrin ;
Messal, Hendrik A. ;
Vareslija, Damir ;
Prekovic, Stefan .
ENDOCRINE-RELATED CANCER, 2025, 32 (01)
[48]   Molecular heterogeneity of luminal breast cancer [J].
S Loi .
Breast Cancer Research, 13
[49]   Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer [J].
Kaboli, Parham Jabbarzadeh ;
Rahmat, Asmah ;
Ismail, Patimah ;
Ling, King-Hwa .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 740 :584-595
[50]   A mechanistic overview of herbal medicine and botanical compounds to target transcriptional factors in Breast cancer [J].
Zhao, Yingke ;
Liu, Yue .
PHARMACOLOGICAL RESEARCH, 2018, 130 :292-302